2613 篇
1075 篇
264385 篇
3265 篇
6305 篇
2228 篇
2769 篇
537 篇
29522 篇
9423 篇
3131 篇
747 篇
2294 篇
1314 篇
449 篇
752 篇
1387 篇
2597 篇
2736 篇
3996 篇
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业,水利、环境和公共设施管理业] [2023-12-05]
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业] [2023-12-05]
[科学研究和技术服务业] [2023-11-30]
The key portfolio decisions that life sciences companies are contemplating today come at a time of contrasts. Big pharma is cash-rich enough to snap up hundreds of small to mid-cap biotech companies.1 And, access to cash for biotech is compressing. Yet the mega mergers that occurred during the comparatively robust M&A era of the 2010s slowed significantly at the beginning of the current decade. Only recently have acquirers closed a handful of sizable deals, suggesting a potential uptick in M&A value in 2023
[科学研究和技术服务业,专用设备制造业] [2023-11-28]
[科学研究和技术服务业] [2023-11-28]
027-87841330